The feasibility of identifying children with primary immunodeficiency disorders: preparation for the polio post-eradication era in Bangladesh.

Abstract:

BACKGROUND:Persons with primary immunodeficiency disorders (PIDD) who receive oral poliovirus vaccine (OPV) or are household contacts of OPV recipients are at risk of excreting immunodeficiency-associated vaccine-derived polioviruses (iVDPVs). iVDPVs can be transmitted and cause paralytic polio. The objective of this study was to determine the feasibility of identifying infants and young children with PIDD in Bangladesh, and among those identified, to estimate the proportion excreting iVDPVs. METHODS:Patients admitted at 5 referral and teaching hospitals from the hospital catchment area were screened for PIDD using a standardized clinical case definition. PIDD was confirmed using results of testing for age-specific quantitative immunoglobulins (QIGs) levels. Stool specimens were collected according to WHO guidelines from children with confirmed PIDD. RESULTS:During February-July 2009, 13 patients were identified who met the clinical case definition for PIDD; their median age was 1.4 years (range: 2 months to 10 years). Six (46%) of the patients had age-specific QIG results that confirmed PIDD. Stool specimens from four patients tested negative for polio vaccine viruses. All four had received OPV between 50 and 264 days prior to study recruitment. CONCLUSION:Identifying children with PIDD at referral and teaching hospitals in Bangladesh is feasible, but a larger number of patients is needed to estimate the risk for iVDPV excretion. The national polio eradication program should expand surveillance for PIDD case-patients and regularly test persons with PIDD for poliovirus excretion. These efforts will be essential for developing effective prevention and control strategies following OPV cessation, especially for densely populated and tropical countries like Bangladesh where even a minimal iVDPV risk could have significant public health consequences.

journal_name

Vaccine

journal_title

Vaccine

authors

Sazzad HM,Rainey JJ,Mach O,Sutter R,Diordista S,Kawser CA,Mobarak R,Alam D,Chowdhury MA,Hossain MJ,Hasan AS,Luby SP

doi

10.1016/j.vaccine.2012.06.017

subject

Has Abstract

pub_date

2012-08-03 00:00:00

pages

5396-400

issue

36

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(12)00858-4

journal_volume

30

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Prevention of perinatal hepatitis B virus transmission in the Netherlands, 2003-2007: children of Chinese mothers are at increased risk of breakthrough infection.

    abstract:BACKGROUND:In the Netherlands, different hepatitis B vaccination schedules have been used for children born to HBV-infected mothers. All schedules included a birth dose of hepatitis B immunoglobuline (HBIg). We assessed determinants of perinatal HBV transmission and determinants of anti-HBs titers in infants born to HB...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.071

    authors: Hahné S,van den Hoek A,Baayen D,van der Sande M,de Melker H,Boot H

    更新日期:2012-02-21 00:00:00

  • Use of a vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies.

    abstract::The vaccination of wild animals against rabies has been developed most extensively in Europe. Experiments have demonstrated the efficacy of a vaccinia-rabies recombinant virus administered by the oral route in foxes. The innocuity of this vaccine was tested in the target species as well as in several non-target wild a...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(90)90129-a

    authors: Brochier B,Thomas I,Bauduin B,Leveau T,Pastoret PP,Languet B,Chappuis G,Desmettre P,Blancou J,Artois M

    更新日期:1990-04-01 00:00:00

  • Catching-up with pentavalent vaccine: Exploring reasons behind lower rotavirus vaccine coverage in El Salvador.

    abstract::Rotavirus vaccine was introduced in El Salvador in 2006 and is recommended to be given concomitantly with DTP-HepB-Haemophilus influenzae type b (pentavalent) vaccine at ages 2 months (upper age limit 15 weeks) and 4 months (upper age limit 8 months) of age. However, rotavirus vaccination coverage continues to lag beh...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2015.07.092

    authors: Suarez-Castaneda E,Burnett E,Elas M,Baltrons R,Pezzoli L,Flannery B,Kleinbaum D,de Oliveira LH,Danovaro-Holliday MC

    更新日期:2015-11-27 00:00:00

  • Evaluation of immune responses to an oral typhoid vaccine, Ty21a, in children from 2 to 5 years of age in Bangladesh.

    abstract::Young children are very susceptible to typhoid fever, emphasizing the need for vaccination in under five age groups. The parenteral Vi polysaccharide vaccine is not immunogenic in children under 2 years and the oral Ty21a vaccine (Vivotif) available in capsular formulation is only recommended for those over 5 years. W...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2014.01.001

    authors: Bhuiyan TR,Choudhury FK,Khanam F,Saha A,Sayeed MA,Salma U,Lundgren A,Sack DA,Svennerholm AM,Qadri F

    更新日期:2014-02-19 00:00:00

  • Severe thrombocytopenia after hepatitis B vaccine in an infant from Turkey.

    abstract::Recombinant hepatitis B vaccine has been used widely in the world since 1991. The side effects of hepatitis B vaccine are seen rarely. In this paper, we present clinical and laboratory progress of an infant who gets severe thrombocytopenia after the second dosage hepatitis B vaccine. Our case is different from other c...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.09.062

    authors: Polat A,Akca H,Dagdeviren E

    更新日期:2008-12-02 00:00:00

  • Production of antibodies and antibody fragments in plants.

    abstract::Our current knowledge allows the generation of transgenic plants that efficiently produce heterologous proteins from plant, bacterial, fungal or animal origin. Among all types of recombinant proteins, antibodies are particularly attractive because of their ability to specifically recognize and bind virtually any type ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(00)00514-4

    authors: Peeters K,De Wilde C,De Jaeger G,Angenon G,Depicker A

    更新日期:2001-03-21 00:00:00

  • Typhoid fever vaccination strategies.

    abstract::Typhoid vaccination is an important component of typhoid fever prevention and control, and is recommended for public health programmatic use in both endemic and outbreak settings. We reviewed experiences with various vaccination strategies using the currently available typhoid vaccines (injectable Vi polysaccharide va...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.04.028

    authors: Date KA,Bentsi-Enchill A,Marks F,Fox K

    更新日期:2015-06-19 00:00:00

  • Safety and immunogenicity of fully liquid DTaP₅-IPV-Hib pediatric combination vaccine (Pediacel®) compared to DTaP₃-HBV-IPV/Hib (Infanrix® Hexa) when coadministered with heptavalent pneumococcal conjugate vaccine (PCV7) as a booster at 11-18 months of age

    abstract::This study compared the safety and immunogenicity of DTaP₅-IPV-Hib vaccine (followed by monovalent hepatitis B vaccine [HBV]) and DTaP₃-HBV-IPV/Hib vaccines, both coadministered with PCV7, as a fourth-dose booster in toddlers 11-18 months who had a hexavalent vaccine primary series. The fever rate within 4 days of DTa...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2012.05.064

    authors: Berner R,Boisnard F,Thomas S,Mwawasi G,Reynolds D

    更新日期:2012-07-27 00:00:00

  • Towards the rational design of Th1 adjuvants.

    abstract::Finding adjuvants in order to enhance immune responses against target immunogens has been a major and recurrent issue for the vaccine industry. It is yet to be solved, most particularly in the context of a growing interest in designing new types of vaccines capable of eliciting Th1 immune responses. A review of synthe...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(01)00193-1

    authors: Moingeon P,Haensler J,Lindberg A

    更新日期:2001-08-14 00:00:00

  • Genetic immunization with GPI-anchored anthrax protective antigen raises combined CD1d- and MHC II-restricted antibody responses by natural killer T cell-mediated help.

    abstract::Studies have demonstrated that lipid rafts ultimately regulate the endocytosis of anthrax toxin via clathrin dependent pathway. Interestingly, GPI-anchored protein rich rafts have also been shown to be transported down to the endocytic pathway to reducing late endosomes. Taking advantage of this parallelism, we tried ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.01.042

    authors: Midha S,Bhatnagar R

    更新日期:2009-03-10 00:00:00

  • Unequal access to vaccines in the WHO European Region during the A(H1N1) influenza pandemic in 2009.

    abstract::In a severe pandemic, rapid production and deployment of vaccines will potentially be critical in mitigating the impact on populations and essential services. We compared access to vaccines and timing of delivery relative to identification of A(H1N1)pdm09 and the geographic progression of the pandemic in the WHO Europ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.06.082

    authors: Jorgensen P,Wasley A,Mereckiene J,Cotter S,Weber JT,Brown CS

    更新日期:2013-08-28 00:00:00

  • Foot-and-mouth disease vaccine potency testing in cattle using homologous and heterologous challenge strains: precision of the "Protection against Podal Generalisation" test.

    abstract::The level of protection conferred by foot-and-mouth disease (FMD) vaccines in primovaccinated animals primarily depends on the potency of the vaccine and the relatedness of the vaccine strain and circulating field isolate. The "Gold Standard" FMD vaccine potency test is the in vivo test performed in the target species...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.04.034

    authors: Goris N,Maradei E,D'Aloia R,Fondevila N,Mattion N,Perez A,Smitsaart E,Nauwynck HJ,La Torre J,Palma E,De Clercq K

    更新日期:2008-06-25 00:00:00

  • Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.

    abstract:BACKGROUND:Use of a polysaccharide vaccine challenge to demonstrate immunologic memory after priming with capsular group C meningococcal conjugate vaccines (MenCC) risks induction of immunologic hyporesponsiveness. For this reason, MenCC vaccines are now used as probes of immunologic memory, however, no studies have de...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2016.10.038

    authors: Pace D,Khatami A,Attard-Montalto S,Voysey M,Finn A,Faust SN,Heath PT,Borrow R,Snape MD,Pollard AJ

    更新日期:2016-12-07 00:00:00

  • Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial.

    abstract::Estimation of the full disease burden caused by Streptococcus pneumoniae is challenging due to the difficulties in assigning the aetiology especially in lower and upper respiratory infections. We estimated the pneumococcal disease burden by using the vaccine-preventable disease incidence (VPDI) of PHiD-CV10 vaccine (G...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2018.02.088

    authors: Palmu AA,Jokinen J,Nieminen H,Rinta-Kokko H,Ruokokoski E,Puumalainen T,Moreira M,Schuerman L,Borys D,Kilpi TM

    更新日期:2018-03-27 00:00:00

  • Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen.

    abstract::As a step in the development of an oral vaccine against ETEC, we evaluated the safety and immunogenicity of CS6, a polymeric protein commonly found on the surface of ETEC. Formulations included 1 and 5mg doses of CS6, either encapsulated in biodegradable polymer poly(D, L)-lactide-co-glycolide (PLG), or as free protei...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/s0264-410x(02)00613-8

    authors: Katz DE,DeLorimier AJ,Wolf MK,Hall ER,Cassels FJ,van Hamont JE,Newcomer RL,Davachi MA,Taylor DN,McQueen CE

    更新日期:2003-01-17 00:00:00

  • Epidemiology of varicella in Haidian district, Beijing, China-2007-2015.

    abstract:BACKGROUND:1-Dose varicella vaccination was recommended for children in Beijing before November 2012. To further control school-based outbreaks and decrease incidence, a 2-dose vaccination was implemented in 2013. We described the varicella epidemiology and assessed impact of the 2-dose vaccination in Haidian district,...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.03.044

    authors: Fu J,Jiang C,Wang J,Zhao F,Ma T,Shi R,Zhao Y,Zhang X

    更新日期:2017-04-25 00:00:00

  • Cost-effectiveness of childhood rotavirus vaccination in Taiwan.

    abstract:OBJECTIVE:Rotavirus is the most common cause of severe diarrhea in children. Two rotavirus vaccines (RotaTeq and Rotarix) have been licensed in Taiwan. We have investigated whether routine infant immunization with either vaccine could be cost-effective in Taiwan. METHODS:We modeled specific disease outcomes including ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.01.023

    authors: Wu CL,Yang YC,Huang LM,Chen KT

    更新日期:2009-03-04 00:00:00

  • Mucosal immunization against hepatitis A: antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid.

    abstract::Hepatitis A caused by hepatitis A virus (HAV) transmitted by the fecal-oral route, results in considerable morbidity and economic loss. Mucosal immunization can be more effective than conventional injection at inducing both local and systemic immunity to HAV. Here we show that co-administration of killed HAV with synt...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.04.015

    authors: Mitchell LA,Joseph A,Kedar E,Barenholz Y,Galun E

    更新日期:2006-06-19 00:00:00

  • Measles risk groups in Spain: implications for the European measles-elimination target.

    abstract::The European Region has set itself the goal of eliminating measles by 2010. Incidence has increased in recent years. This study sought to investigate outbreaks in Spain in the period 2005-2007, in order to identify measles-vulnerable groups and compare Spain to other European countries which have also had measles outb...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2009.04.024

    authors: Peña-Rey I,Martínez de Aragón V,Mosquera M,de Ory F,Echevarría JE,Measles Elimination Plan Working Group in Spain.

    更新日期:2009-06-19 00:00:00

  • Protection against Schistosoma mansoni utilizing DNA vaccination with genes encoding Cu/Zn cytosolic superoxide dismutase, signal peptide-containing superoxide dismutase and glutathione peroxidase enzymes.

    abstract::Protection against Schistosoma mansoni infection in C57BL/6 female mice was evaluated by two DNA vaccination strategies. Mice were either vaccinated by intramuscular injection with pcDNAI/Amp constructs encoding either Cu/Zn cytosolic superoxide dismutase (CT-SOD), signal peptide-containing SOD (SP-SOD), glutathione p...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00535-8

    authors: Shalaby KA,Yin L,Thakur A,Christen L,Niles EG,LoVerde PT

    更新日期:2003-12-08 00:00:00

  • Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine.

    abstract::We performed a randomized, controlled clinical trial to characterize the evolution of the adverse events associated with the fifth consecutive dose of an acellular pertussis vaccine, and to assess the level of discomfort associated with the injection and the attitude of parents concerning these events. A total of 505 ...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1016/s0264-410x(03)00173-7

    authors: Halperin SA,Scheifele D,Mills E,Guasparini R,Humphreys G,Barreto L,Smith B

    更新日期:2003-06-02 00:00:00

  • Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.

    abstract::Malaria caused by Plasmodium falciparum continues to threaten millions of people living in the tropical parts of the world. A vaccine that confers sterile and life-long protection remains elusive despite more than 30years of effort and resources invested in solving this problem. Antibodies to a malaria vaccine candida...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2017.05.070

    authors: Genito CJ,Beck Z,Phares TW,Kalle F,Limbach KJ,Stefaniak ME,Patterson NB,Bergmann-Leitner ES,Waters NC,Matyas GR,Alving CR,Dutta S

    更新日期:2017-07-05 00:00:00

  • Safety of yellow fever vaccine administration in confirmed egg-allergic patients.

    abstract::Yellow fever vaccine (YFV) is recommended in endemic areas but represents a risk for egg-allergic patients, as it is cultivated in embryonated eggs. This study aims to describe the outcomes of yellow fever vaccination in patients with confirmed egg allergy (EA). Methods:A prospective study was conducted from January 2...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.08.020

    authors: Gerhardt CMB,Castro APBM,Pastorino AC,Dorna MB,Nunes-Santos CJ,Aquilante BP,Miyaji KT,Lopes MH

    更新日期:2020-09-29 00:00:00

  • Influenza in the Asia-Pacific region: Findings and recommendations from the Global Influenza Initiative.

    abstract::The fourth roundtable meeting of the Global Influenza Initiative (GII) was held in Hong Kong, China, in July 2015. An objective of this meeting was to gain a broader understanding of the epidemiology, surveillance, vaccination policies and programs, and obstacles to vaccination of influenza in the Asia-Pacific region ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2016.12.064

    authors: Cowling BJ,Caini S,Chotpitayasunondh T,Djauzi S,Gatchalian SR,Huang QS,Koul PA,Lee PI,Muttalif AR,Plotkin S,Global Influenza Initiative.

    更新日期:2017-02-07 00:00:00

  • Neuraminidase inhibiting antibody responses in pigs differ between influenza A virus N2 lineages and by vaccine type.

    abstract::The neuraminidase (NA) protein of influenza A viruses (IAV) has important functional roles in the viral replication cycle. Antibodies specific to NA can reduce viral replication and limit disease severity, but are not routinely measured. We analyzed NA inhibiting (NI) antibody titers in serum and respiratory specimens...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.06.001

    authors: Sandbulte MR,Gauger PC,Kitikoon P,Chen H,Perez DR,Roth JA,Vincent AL

    更新日期:2016-07-19 00:00:00

  • Myxomavirus as a vector for the immunisation of sheep: protection study against challenge with bluetongue virus.

    abstract::Recombinant poxviruses are well suited for the development of new vaccine vectors. Our previous data supported the idea that Myxomavirus (MYXV) is efficient at priming antibody responses in sheep. To provide definitive evidence on the potential of MYXV for vaccination against infectious diseases in ruminants, we inves...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.12.108

    authors: Top S,Foucras G,Deplanche M,Rives G,Calvalido J,Comtet L,Bertagnoli S,Meyer G

    更新日期:2012-02-21 00:00:00

  • Antibodies against Haemophilus influenzae type b in The Gambia: investigating the extent of protection across age groups.

    abstract::Following a landmark clinical trial, the vaccine against Haemophilus influenzae type b (Hib) was introduced in The Gambia in 1997. Whilst the immunogenicity of this vaccine is well established subsequent to the doses administered under the EPI schedule, little data exists assessing longevity of protection, using serol...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.06.078

    authors: Idoko OT,Roberts E,Cox M,Jafali J,Njie-Jobe J,Mackenzie G,Ota MO,Kampmann B

    更新日期:2014-08-06 00:00:00

  • Age-related trends in the timeliness and prediction of medical visits, hospitalizations and deaths due to pneumonia and influenza, British Columbia, Canada, 1998-2004.

    abstract::The influenza immunization program in North America has been primarily designed to provide direct benefit to vaccinated individuals at highest risk of serious influenza outcomes. Some evidence suggests that immunization of certain age groups may also extend indirect protective benefit to vulnerable populations. Our go...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.11.090

    authors: Sebastian R,Skowronski DM,Chong M,Dhaliwal J,Brownstein JS

    更新日期:2008-03-04 00:00:00

  • Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.

    abstract::To date, most peptide-based vaccines evaluated for the treatment of cancer have consisted of one or few peptides. However, as a greater number of peptide antigens become available for use in experimental therapies, it is important to establish the feasibility of combining multi-peptide reagents as individual peptide m...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.01.018

    authors: Chianese-Bullock KA,Lewis ST,Sherman NE,Shannon JD,Slingluff CL Jr

    更新日期:2009-03-10 00:00:00

  • Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level.

    abstract::In 2005, in accordance with recommendations made by the European Medicines Agency, the Italian Drug Agency ordered withdrawal of the hexavalent Hexavac(®) vaccine (Sanofi Pasteur MSD) from the market. Concerns had been raised about the low immunogenicity of the hepatitis B virus component of the vaccine, assessed by m...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.11.029

    authors: Carollo M,Palazzo R,Bianco M,Pandolfi E,Chionne P,Fedele G,Tozzi AE,Carsetti R,Romanò L,Ausiello CM

    更新日期:2013-01-07 00:00:00